CYBIN INC (CYBN) Stock News

NYSEARCA:CYBN - NYSE Arca - CA23256X4075 - Common Stock - Currency: USD

7.15 -0.45 (-5.92%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CYBN Latest News, Press Relases and Analysis

All

Press Releases

21 hours ago - By: Cybin Inc.

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

7 days ago - By: Cybin Inc.

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

8 days ago - By: Cybin Inc.

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

a month ago - By: Cybin Inc.

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

a month ago - By: MarketBeat - Mentions: RZLV AUR TSLA UBER

3 High-Risk, High-Reward Stocks With Explosive Upside

a month ago - By: Cybin Inc.

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

a month ago - By: Cybin Inc.

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

a month ago - By: Cybin Inc.

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

2 months ago - By: Cybin Inc.

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

2 months ago - By: Cybin Inc.

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

2 months ago - By: Cybin Inc.

Cybin to Participate in the 2025 Psychedelic Science Conference

2 months ago - By: Benzinga

Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming

2 months ago - By: Cybin Inc.

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

3 months ago - By: Benzinga - Mentions: ATAI CMPS SEEL MNMD ...

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors

3 months ago - By: Cybin Inc.

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

3 months ago - By: Cybin Inc.

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

3 months ago - By: Cybin Inc.

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

3 months ago - By: Cybin Inc.

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

3 months ago - By: Cybin Inc.

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

4 months ago - By: Cybin Inc.

Cybin to Participate at the 28th Annual Milken Institute Global Conference

4 months ago - By: Cybin Inc.

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

4 months ago - By: Cybin Inc.

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

4 months ago - By: Investor's Business Daily - Mentions: RY RY.CA MRNA PFE ...

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

6 months ago - By: Investor's Business Daily - Mentions: PCVX MRNA MNMD CMPS

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.

6 months ago - By: Cybin Inc.

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

6 months ago - By: Investor's Business Daily - Mentions: MRNA BNTX PFE GSK

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

7 months ago - By: Cybin Inc.

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

7 months ago - By: Cybin Inc.

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

7 months ago - By: Cybin Inc.

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

8 months ago - By: Cybin Inc.

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

8 months ago - By: Cybin Inc.

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

9 months ago - By: The Motley Fool - Mentions: CMPS MNMD AACG

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

9 months ago - By: Cybin Inc.

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

9 months ago - By: Cybin Inc.

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024